The Germany-based pharma company Boehringer Ingelheim has experienced major growth in recent years, with 2020 net sales reaching EUR 19.6 billion. This expansion has been supported by increased reliance on real-world data (RWD) and real-world evidence (RWE) at every level of clinical development. Doing so required a data solution that could adapt to changing demands across the product lifecycle.
According to Clinical Leader, “To accomplish its short-term and long-term goals, the Boehringer Ingelheim team turned to IBM® Watson Health® and the global life sciences team for assistance in updating its systems and processes with rich, deidentified real-world data from the IBM MarketScan® Research Databases.”
Read more by clicking here.
(Source: Clinical Leader, May 16th, 2022)